JNJ-77242113, JNJ-77242113 clinical trials

A Single-dose, Open-label, Randomized, Crossover Study to Assess the Relative Oral Bioavailability of a JNJ-77242113 Phase 3 Immediate-release Tablet Formulation with Respect to the Phase 2 Immediate-release Tablet Formulation and to Assess the Food Effect of a JNJ-77242113 Phase 3 Immediate-release Tablet Formulation in Healthy Participants

This study is looking at a new medicine called JNJ-77242113 for inflammatory conditions. It's comparing two versions of the tablet and seeing how food affects one of them. The aim is to understand how well the body absorbs the medicine.